Please assess the completion status of the following clinical trial:

Trial Title: Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with biopsy proven AL amyloidosis.~2. Patients ≥ 18 years of age are eligible.~3. Patient must provide informed consent.~4. All patients must have measurable amyloid organ involvement of a vital organ (eg. heart, liver, kidneys). Localized amyloidosis will also be eligible as long as the amyloid involvement is radiologically measurable.~5. A negative pregnancy test will be required for all women of child bearing potential. Breast feeding is not permitted.~6. Patients who have previously been taking doxycycline will be eligible as long as there is no contraindication to stay on doxycycline 100 mg twice daily (BID) for 1 year in the opinion of the treating physician.~7. Creatinine clearance of \>25 ml/min.~Exclusion Criteria:~1. Patients with severe malabsorption syndrome precluding absorption of oral agents will be excluded.~2. Known intolerance or allergic reactions with doxycycline.~3. Previous chemotherapy for AL amyloidosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).